18F-fdg pet scanning in pulmonary amyloidosis

Misbah Baqir, Val Lowe, Eunhee S. Yi, Jay H Ryu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

18F-FDG PET plays an important role in the evaluation of patients with lung malignancies but can lead to false-positive and falsenegative results. Very little is known about 18F-FDG PET scanning in amyloidosis. Methods: A computer-assisted search of medical records was conducted to identify subjects with pulmonary amyloidosis (confirmed by biopsy) who were seen at the Mayo Clinic during a 15-y period between January 1, 1997, and December 31, 2011, and had a PET scan available for current review. Results: Eighteen patients were diagnosed to have amyloidosis by lung biopsy (15 surgical, 2 transthoracic needle, and 1 bronchoscopic). The mean age of the patients was 64.8 y (range, 32-80 y). Seventeen patients had primary amyloidosis, including 5 with Sjögren syndrome, 1 with rheumatoid arthritis, and 1 with multiple myeloma. The most common abnormal findings on the chest CT scan were pulmonary nodules (n = 14), followed by cysts (n 5 6) and reticular opacities (n = 4). Eight patients had positive 18F-FDG PET results (intrathoracic 18F-FDG uptake), including 4 patients with coexisting mucosa-associated lymphoid tissue lymphoma (maximal standardized uptake value [SUVmax] range, 3.1-6.7) and 1 patient with a pleural plasmacytoma (SUVmax, 7.2); the remaining 3 patients had amyloid only (SUVmax range, 2.1-3.2). Ten patients with negative PET results included 3 additional patients with mucosa- associated lymphoid tissue lymphoma. Conclusion: Positive 18F-FDG PET results, especially with an SUVmax of more than 3, in patients with pulmonary amyloidosis should raise suspicion about associated lymphoma or plasmacytoma, but negative PET results do not exclude the presence of such neoplasms.

Original languageEnglish (US)
Pages (from-to)565-568
Number of pages4
JournalJournal of Nuclear Medicine
Volume55
Issue number4
DOIs
StatePublished - Apr 1 2014

Fingerprint

Pets
Amyloidosis
Lung
Fluorodeoxyglucose F18
Marginal Zone B-Cell Lymphoma
Plasmacytoma
Biopsy
Multiple Myeloma
Amyloid
Positron-Emission Tomography
Needles
Medical Records
Cysts
Lymphoma
Rheumatoid Arthritis
Neoplasms
Thorax

Keywords

  • Amyloidosis
  • B-cell
  • Lymphoma
  • Marginal zone
  • Positronemission tomography
  • Pulmonary nodule
  • Sjögren's syndrome

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

18F-fdg pet scanning in pulmonary amyloidosis. / Baqir, Misbah; Lowe, Val; Yi, Eunhee S.; Ryu, Jay H.

In: Journal of Nuclear Medicine, Vol. 55, No. 4, 01.04.2014, p. 565-568.

Research output: Contribution to journalArticle

Baqir, Misbah ; Lowe, Val ; Yi, Eunhee S. ; Ryu, Jay H. / 18F-fdg pet scanning in pulmonary amyloidosis. In: Journal of Nuclear Medicine. 2014 ; Vol. 55, No. 4. pp. 565-568.
@article{1b304c11ad7143cc9e16ad29bedf81ef,
title = "18F-fdg pet scanning in pulmonary amyloidosis",
abstract = "18F-FDG PET plays an important role in the evaluation of patients with lung malignancies but can lead to false-positive and falsenegative results. Very little is known about 18F-FDG PET scanning in amyloidosis. Methods: A computer-assisted search of medical records was conducted to identify subjects with pulmonary amyloidosis (confirmed by biopsy) who were seen at the Mayo Clinic during a 15-y period between January 1, 1997, and December 31, 2011, and had a PET scan available for current review. Results: Eighteen patients were diagnosed to have amyloidosis by lung biopsy (15 surgical, 2 transthoracic needle, and 1 bronchoscopic). The mean age of the patients was 64.8 y (range, 32-80 y). Seventeen patients had primary amyloidosis, including 5 with Sj{\"o}gren syndrome, 1 with rheumatoid arthritis, and 1 with multiple myeloma. The most common abnormal findings on the chest CT scan were pulmonary nodules (n = 14), followed by cysts (n 5 6) and reticular opacities (n = 4). Eight patients had positive 18F-FDG PET results (intrathoracic 18F-FDG uptake), including 4 patients with coexisting mucosa-associated lymphoid tissue lymphoma (maximal standardized uptake value [SUVmax] range, 3.1-6.7) and 1 patient with a pleural plasmacytoma (SUVmax, 7.2); the remaining 3 patients had amyloid only (SUVmax range, 2.1-3.2). Ten patients with negative PET results included 3 additional patients with mucosa- associated lymphoid tissue lymphoma. Conclusion: Positive 18F-FDG PET results, especially with an SUVmax of more than 3, in patients with pulmonary amyloidosis should raise suspicion about associated lymphoma or plasmacytoma, but negative PET results do not exclude the presence of such neoplasms.",
keywords = "Amyloidosis, B-cell, Lymphoma, Marginal zone, Positronemission tomography, Pulmonary nodule, Sj{\"o}gren's syndrome",
author = "Misbah Baqir and Val Lowe and Yi, {Eunhee S.} and Ryu, {Jay H}",
year = "2014",
month = "4",
day = "1",
doi = "10.2967/jnumed.113.130823",
language = "English (US)",
volume = "55",
pages = "565--568",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "4",

}

TY - JOUR

T1 - 18F-fdg pet scanning in pulmonary amyloidosis

AU - Baqir, Misbah

AU - Lowe, Val

AU - Yi, Eunhee S.

AU - Ryu, Jay H

PY - 2014/4/1

Y1 - 2014/4/1

N2 - 18F-FDG PET plays an important role in the evaluation of patients with lung malignancies but can lead to false-positive and falsenegative results. Very little is known about 18F-FDG PET scanning in amyloidosis. Methods: A computer-assisted search of medical records was conducted to identify subjects with pulmonary amyloidosis (confirmed by biopsy) who were seen at the Mayo Clinic during a 15-y period between January 1, 1997, and December 31, 2011, and had a PET scan available for current review. Results: Eighteen patients were diagnosed to have amyloidosis by lung biopsy (15 surgical, 2 transthoracic needle, and 1 bronchoscopic). The mean age of the patients was 64.8 y (range, 32-80 y). Seventeen patients had primary amyloidosis, including 5 with Sjögren syndrome, 1 with rheumatoid arthritis, and 1 with multiple myeloma. The most common abnormal findings on the chest CT scan were pulmonary nodules (n = 14), followed by cysts (n 5 6) and reticular opacities (n = 4). Eight patients had positive 18F-FDG PET results (intrathoracic 18F-FDG uptake), including 4 patients with coexisting mucosa-associated lymphoid tissue lymphoma (maximal standardized uptake value [SUVmax] range, 3.1-6.7) and 1 patient with a pleural plasmacytoma (SUVmax, 7.2); the remaining 3 patients had amyloid only (SUVmax range, 2.1-3.2). Ten patients with negative PET results included 3 additional patients with mucosa- associated lymphoid tissue lymphoma. Conclusion: Positive 18F-FDG PET results, especially with an SUVmax of more than 3, in patients with pulmonary amyloidosis should raise suspicion about associated lymphoma or plasmacytoma, but negative PET results do not exclude the presence of such neoplasms.

AB - 18F-FDG PET plays an important role in the evaluation of patients with lung malignancies but can lead to false-positive and falsenegative results. Very little is known about 18F-FDG PET scanning in amyloidosis. Methods: A computer-assisted search of medical records was conducted to identify subjects with pulmonary amyloidosis (confirmed by biopsy) who were seen at the Mayo Clinic during a 15-y period between January 1, 1997, and December 31, 2011, and had a PET scan available for current review. Results: Eighteen patients were diagnosed to have amyloidosis by lung biopsy (15 surgical, 2 transthoracic needle, and 1 bronchoscopic). The mean age of the patients was 64.8 y (range, 32-80 y). Seventeen patients had primary amyloidosis, including 5 with Sjögren syndrome, 1 with rheumatoid arthritis, and 1 with multiple myeloma. The most common abnormal findings on the chest CT scan were pulmonary nodules (n = 14), followed by cysts (n 5 6) and reticular opacities (n = 4). Eight patients had positive 18F-FDG PET results (intrathoracic 18F-FDG uptake), including 4 patients with coexisting mucosa-associated lymphoid tissue lymphoma (maximal standardized uptake value [SUVmax] range, 3.1-6.7) and 1 patient with a pleural plasmacytoma (SUVmax, 7.2); the remaining 3 patients had amyloid only (SUVmax range, 2.1-3.2). Ten patients with negative PET results included 3 additional patients with mucosa- associated lymphoid tissue lymphoma. Conclusion: Positive 18F-FDG PET results, especially with an SUVmax of more than 3, in patients with pulmonary amyloidosis should raise suspicion about associated lymphoma or plasmacytoma, but negative PET results do not exclude the presence of such neoplasms.

KW - Amyloidosis

KW - B-cell

KW - Lymphoma

KW - Marginal zone

KW - Positronemission tomography

KW - Pulmonary nodule

KW - Sjögren's syndrome

UR - http://www.scopus.com/inward/record.url?scp=84901306692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901306692&partnerID=8YFLogxK

U2 - 10.2967/jnumed.113.130823

DO - 10.2967/jnumed.113.130823

M3 - Article

C2 - 24556593

AN - SCOPUS:84901306692

VL - 55

SP - 565

EP - 568

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 4

ER -